Fig. 2.
Fig. 2. Recipients of perforin-deficient B6.pfp−/−donor T cells develop leukemia. / All C3FeB6F1/J recipients underwent transplantation, as described in Figure 1. However, the leukemia cell dose was increased to 5000 cells/mouse, and the donor T-cell dose was decreased to 1 × 106 cells/mouse. Percentages of animals that died of leukemia from combined experiments with 16 recipients per group are shown. Recipients of TCD-BM + B6.pfp−/− T cells displayed a significantly higher mortality rate from leukemia (56%) than recipients of TCD-BM + B6 (or B6.gld) T cells (0%).

Recipients of perforin-deficient B6.pfp−/−donor T cells develop leukemia.

All C3FeB6F1/J recipients underwent transplantation, as described in Figure 1. However, the leukemia cell dose was increased to 5000 cells/mouse, and the donor T-cell dose was decreased to 1 × 106 cells/mouse. Percentages of animals that died of leukemia from combined experiments with 16 recipients per group are shown. Recipients of TCD-BM + B6.pfp−/− T cells displayed a significantly higher mortality rate from leukemia (56%) than recipients of TCD-BM + B6 (or B6.gld) T cells (0%).

Close Modal

or Create an Account

Close Modal
Close Modal